Hims & Hers Faces Class Action Lawsuit Following FTC Complaint

Key Facts

1Hims & Hers Health faces a securities class action lawsuit accusing the company and executives of business misconduct.

2The lawsuit follows the revelation of a sweeping federal complaint by the Federal Trade Commission (FTC) against the company.

Amid intensifying regulatory scrutiny over health-tech firms, Hims & Hers Health and its executives are facing a securities class action lawsuit accusing them of business misconduct. This legal action follows the revelation of a sweeping federal complaint filed by the Federal Trade Commission (FTC) against the company. According to reports, these allegations have triggered significant investor losses as the stock price reacted to the disclosure of the alleged misconduct.

The lawsuit centers on allegations that the company shared sensitive consumer health information with third-party advertising platforms and charged for prescriptions almost immediately after intake forms were submitted, bypassing promised medical consultations. Consequently, the company is expected to face heightened regulatory oversight and potential penalties. These developments have raised concerns regarding the adequacy of the firm's internal controls and the accuracy of its communications with investors.

As of September 2, 2026, updated price levels for HIMS are unavailable in the current database, though the outlook remains bearish due to potential legal liabilities. Investors are closely monitoring upcoming judicial developments, including the lead plaintiff deadline in November. Market participants are also looking toward broader US economic catalysts, such as Initial Jobless Claims, to gauge overall sentiment in the near term.